After being fed a high-fat high-cholesterol diet for 12 weeks, evolocumab prevented hyperlipidemia and atherosclerotic plaque formation, suggesting that the LDLR+/− hamster is a suitable animal model to evaluate the therapeutic effects of drug candidates which target PCSK9 [48]. The gene discussed is LDLR; the disease is hyperlipidemia.